Nucleai

💙 This Valentine’s Day, we’re showing love for what drives us—pushing the boundaries of AI-powered spatial biomarkers to make a real impact in precision medicine. Because innovation and dedication are at the heart of everything we do! #ValentinesDay #PrecisionMedicine #SpatialBiomarkers

This #WorldCancerDay, we are #UnitedByUnique in advancing AI-powered #biomarkers and diagnostics to enable more precise and tailored therapies. By harnessing spatial biology and cutting-edge technology, we help push the boundaries of precision oncology—driving better outcomes for patients worldwide. 🎗️ #PrecisionOncology #DigitalPathology #AIPathology #SpatialBiomarkers

🔎 The 𝑭𝒊𝒓𝒔𝒕 AI-Powered Pathology Solution Deployed for Prospective Enrollment in a Multispecific Trial! 🚀 Selecting the right patients for multispecific therapies depends on accurately assessing co-expression of target antigens, but traditional IHC methods can be subjective and challenging. Learn how our AI-powered spatial analysis can enable pathologists to accurately score co-expressing cells, providing a scalable and reproducible approach—and how our three-way partnership with a Top 10 Biopharma and a leading IVD pathology company has established a pioneering, industry-leading framework for deploying AI-powered IHC assays for prospective trial enrollment. 🔗 read the full case study → https://hubs.li/Q034PKY20

We believe that spatial insights are set to transform patient care in the not-too-distant future. From leveraging information from H&E and IHC assays (like HER2 or PD-L1) to harnessing data from complex assays like multiplex immunofluorescence, these advancements are paving the way for more precise diagnostics and effective treatments. 🎥 Watch the webinar on-demand to learn how spatial biomarkers are driving the future of patient care - link in first comment. #spatialbiomarker #CDx #IHC #multiplexIF #H&E #diagnostics #biomarkers #precisionmedicine

How can AI-augmented scoring of the bystander effect improve ADC patient selection? In our latest case study, discover how we applied our AI-powered Spatial Proximity Score (SPS) model to an ADC developer’s patient cohort, proposing a framework to evaluate the bystander antitumor activity of their drug. By incorporating SPS-based scoring, we demonstrated its potential to expand the pool of treatment-eligible patients, including those beyond traditional antigen-positivity thresholds. 🔗 Read the Full Case Study → https://hubs.li/Q033W56n0

🔎Discover how AI-powered spatial biomarkers are optimizing drug co-positioning strategies in ulcerative colitis. With Nucleai's AI spatial analysis solutions, you can: ✔️Uncover Novel Biomarkers: Identified Marker X to predict long-term response at 8 weeks post-treatment. ✔️Make Optimized Clinical Decisions: If validated in a larger cohort, could enable switching non-responders to a different drug within the same portfolio. ✔️Streamline QC Workflow: Delivered cleaner datasets and actionable insights through a robust QC process. 👉 https://hubs.ly/Q032Xb4p0

Next-generation therapies like ADCs, bispecifics, and immunotherapy combinations rely on spatial biomarkers, driving the need for increasingly complex assays. With limited tissue samples, a key challenge is extracting maximum insights without exhausting valuable material. Discover how AI is unlocking the potential of spatial biomarkers—enabling deeper analysis from the same slides, preserving tissue, and advancing drug development. 📢 Watch the webinar on-demand to learn how AI is advancing spatial biology and precision medicine - link in first comment. #spatialbiomarkers #AIPathology #DigitalPathology #PrecisionMedicine #biomarkers #PrecisionOncology

One journey, four founders—proud to stand alongside Thomas Clozel from Owkin, Andrew Beck from PathAI, and Thomas Fuchs Founder of Paige, shaping the future of #AI and #healthcare together. Winning together! #JPM25 Nucleai

🌠 Our new Resource Library is 𝗟𝗜𝗩𝗘! Explore case studies, publications, blogs, and webinars showcasing our cutting-edge AI pathology solutions—driving breakthroughs in next-gen treatments and precision medicine. Explore now: https://bit.ly/3DVYMCy #AIPathology #DigitalPathology #PrecisionMedicine #SpatialBiomarkers #CDx

𝙏𝙝𝙚 𝙛𝙪𝙩𝙪𝙧𝙚 𝙤𝙛 𝙘𝙖𝙣𝙘𝙚𝙧 𝙙𝙞𝙖𝙜𝙣𝙤𝙨𝙩𝙞𝙘𝙨 𝙞𝙨 𝙝𝙚𝙧𝙚—𝙖𝙣𝙙 𝙞𝙩’𝙨 𝘼𝙄-𝙥𝙤𝙬𝙚𝙧𝙚𝙙. We believe that AI-powered spatial proteomics can unlock the hidden treatment insights within every patient’s biopsy and transform cancer care. From ADCs to bispecifics, we’re partnering with top biopharma to advance clinical trials and next-gen treatments. Join us in shaping the future of precision oncology, where a single test can screen across multiple ADC trials and treatments. Let’s connect at JPM 2025! https://bit.ly/3Cexdnr #SpatialBiomarkers #CDx #JPM25 #PrecisionMedicine #PrecisionOncology #AIPathology #DigitalPathology